Productos destacados

Soluciones Innovadoras para Profesionales Sanitarios.

Secciones destacadas

Referencias

  1. GSK Data on File. Document number 2019N409506_00, junio 2019.
  2. Shingrix - Información para prescribir aprobada en CARICAM.
  3. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32(15):1745-53.
  4. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
  5. Bharucha T, Ming D, Breuer J. A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017 Aug;13(8):1789-97.
  6. Merck Sharp & Dohme. Merck Zoster Vaccine European public assessment report, Annex I: Summary of product characteristics: EMA; [updated January 2019; accessed May 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/zostavax-epar-product-information_en.pdf.
  7. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012 Aug;24(4):494-500.

PM-RCH-NA-WCNT-210003
Fecha de preparación Agosto 2024 | Fecha de expiración Agosto 2026.